Author

Elyse A. Olesinski

Massachusetts General HospitalORCID 0000-0002-2717-9755Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

Ahmed M. MamdouhiD· 2 shared Fang Qi Lim· 2 shared Koji ItahanaiD· 2 shared Shaista Shabbir JasdanwalaiD· 2 shared Shruti BhattiD· 2 shared Yang Mi· 2 shared Aarthi Nivasini MaheshiD· 1 shared Alexandre PuissantiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ahmed M. MamdouhORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 28, 2025

TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade

Ahmed M. Mamdouh, Elyse A. Olesinski, Fang Qi Lim…·Shruti Bhatt

This study identifies that TP53 mutations in AML lead to resistance to VenAza therapy by blocking caspase-3/7 activation after mitochondrial outer membrane permeabilization.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 17, 2025

BIRC5 dependency defines a targetable vulnerability in TP53 mutant acute myeloid leukemia

Ahmed M. Mamdouh, Fang Qi Lim, Yang Mi…·Shruti Bhatt

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky